Agilent Technologies, Inc. (NYSE:A) Given Average Rating of “Moderate Buy” by Analysts

Shares of Agilent Technologies, Inc. (NYSE:A) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $149.6154.

A has been the subject of several research analyst reports. UBS Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and increased their price objective for the company from $130.00 to $170.00 in a research report on Wednesday, October 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a research report on Wednesday, October 8th. They set a “buy” rating and a $165.00 price target for the company. Finally, TD Cowen raised their price target on shares of Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th.

Agilent Technologies Stock Up 1.2%

NYSE:A opened at $146.46 on Wednesday. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The stock has a market capitalization of $41.52 billion, a P/E ratio of 34.38, a P/E/G ratio of 4.67 and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The company’s 50-day simple moving average is $134.05 and its 200-day simple moving average is $121.62.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.67 billion. During the same period last year, the business earned $1.32 EPS. The company’s revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities analysts anticipate that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th were paid a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Institutional Investors Weigh In On Agilent Technologies

Institutional investors have recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC boosted its position in shares of Agilent Technologies by 16.9% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 4,644 shares of the medical research company’s stock valued at $597,000 after acquiring an additional 673 shares during the last quarter. Physician Wealth Advisors Inc. boosted its position in shares of Agilent Technologies by 490.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 236 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 196 shares during the last quarter. Callan Family Office LLC boosted its position in shares of Agilent Technologies by 8.8% during the 3rd quarter. Callan Family Office LLC now owns 15,196 shares of the medical research company’s stock valued at $1,950,000 after acquiring an additional 1,234 shares during the last quarter. Atlantic Union Bankshares Corp boosted its position in shares of Agilent Technologies by 22.4% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 832 shares of the medical research company’s stock valued at $107,000 after acquiring an additional 152 shares during the last quarter. Finally, Jones Financial Companies Lllp boosted its position in shares of Agilent Technologies by 6.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 5,618 shares of the medical research company’s stock valued at $693,000 after acquiring an additional 339 shares during the last quarter. Institutional investors and hedge funds own 87.41% of the company’s stock.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.